<DOC>
	<DOCNO>NCT01440946</DOCNO>
	<brief_summary>The primary objective study evaluate safety Recombinant Human Coagulation Factor IX Fc Fusion Protein ( rFIXFc ) previously treat pediatric subject hemophilia B . Secondary objective study study population follow : evaluate efficacy rFIXFc prevention treatment bleed episode ; evaluate ass pharmacokinetics ( PK ) rFIXFc ; evaluate rFIXFc consumption prevention treatment bleed episode</brief_summary>
	<brief_title>Study Recombinant Coagulation Factor IX Fc Fusion Protein , BIIB029 , Previously Treated Pediatric Participants With Hemophilia B</brief_title>
	<detailed_description>At Baseline visit ( 28 ± 7 day prior Day 1 ) , participant receive single IV injection prestudy FIX 10 ( ±5 ) minute clinic medical supervision dose 50 IU/kg . A washout period FIX treatment require prior administration prestudy FIX prior rFIXFc . A PK assessment do prestudy FIX also do rFIXFc Day 1 . After complete PK assessment , participant begin weekly prophylactic treatment rFIXFc approximately 50 week , obtain 50 EDs . One ED define 24-hour period participant receive 1 dos rFIXFc , time first injection rFIXFc define start ED .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Severe hemophilia B define ≤ 2 IU/dl ( ≤ 2 % ) endogenous FIX Male &lt; 12 year weight ≥ 13 kg History least 50 documented prior exposure day FIX No history , currently detectable , inhibitor Key Other coagulation disorder addition Hemophilia B History anaphylaxis associate FIX IV immunoglobulin administration NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>